CompletedEUCTR 2010-020951-30
A Phase 4, Open-label, Multicentre, 2-Year Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents Aged 6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)
This historical record does not confirm current site availability.
Historical research recordMultiple countries
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Belgium · Germany and 7 more locations
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 300
- Sponsor
- Shire Pharmaceutical Development Ltd
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United Kingdom, Belgium, Germany, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2010-020951-30
- Official title
Show the full official title
A Phase 4, Open-label, Multicentre, 2-Year Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents Aged 6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belgium · Germany · Hungary
6 more locations
- Italy
- Netherlands
- Poland
- Spain
- Sweden
- United Kingdom
Registry details
Historical country statuses
- Belgium — Completed
- Germany — Completed
- Spain — Completed
- United Kingdom — Completed
- Hungary — Completed
- Italy — Completed
- Netherlands — Completed
- Poland — Completed
- Sweden — Completed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Shire Pharmaceutical Development Ltd, a pharmaceutical company.
Want to explore more studies?
Explore studiesRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...